ARCHIVES

FDA Hears More Criticism On Cancer Drug Endpoints; Joint Conferences On Criteria Recommended

This article is from The Cancer Letter archive.

Vol. 15 No. 30 | July 28, 1989

Download PDF Visit The Full Archive

Related Articles

Freireich’s Seven Laws To Protect Against Obstacles To Clinical Research

May 14, 1976

GA Draft Report Lukewarm On Cancer Survival Improvement; NCI Says It Is “Opinion, Not Fact”

April 3, 1987

340B Drug Discount Program: HRSA Defends Orphan Drug Rule

June 20, 2014

Letter: Palestinian Authority Not Yet A Country

June 14, 1996

Xeloda, Taxotere, Herceptin Combination May Benefit Invasive Breast Cancer

January 25, 2008

Low Total Cholesterol Linked To Higher Risk Of Cancer; Higher HDL Associated With Decreased Risk Of Cancer

November 27, 2009